Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Patient response positive in Xultophy trial
November 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

STOCKHOLM, Sweden—Novo Nordisk recently shared new findings from its DUAL V Phase 3b clinical trial, which evaluated the safety and efficacy of Xultophy (IDegLira), a once-daily single-injection combination of Tresiba (insulin degludec) and Victoza (liraglutide), compared to further intensification with insulin glargine U100 in adults with type 2 diabetes uncontrolled on insulin glargine U100. The study saw greater improvements in treatment-related satisfaction and patient-reported physical health in patients treated with Xultophy versus insulin glargine U100. Patient-reported outcomes (PRO), assessed with the TRIM-D and SF-36 questionnaires, were also positive, with Xultophy patients seeing greater improvement in treatment burden and diabetes management than patients receiving insulin glargine U100. The findings based on the PRO questionnaires were shared at the 51st European Association for the Study of Diabetes.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.